NKG2D Receptor-Based CAR-T Cell #ASH19
David Gilham, MD of Celyad discusses a human NKG2D receptor-based CAR-T cell that potentially targets 80% of all cancers.
Related Articles
Cancer Warrior T-Shirt – OncologyTube – Unisex
Rock the Cancer Warrior T-Shirt! Bold, comfy, and perfect for researchers, nurses, oncologists, and patients. Available in 10 colors—proceeds support cancer awareness. Wear your strength!…
Steve Jobs Death, in 2025 could oncologist save him from pancreatic cancer?
Reflecting on Steve Jobs death, we examine his cancer journey and the evolution of treatments. What if he had today’s options?
Enfortumab Vedotin Plus Pembrolizumab vs. Chemotherapy for Untreated la/mUC: EV-302 Study Update
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At the 2025 ASCO Genitourinary Cancers…
Encorafenib + cetuximab (EC) BREAKWATER Study Reveals Breakthrough in Treating BRAF V600E-Mutant Metastatic Colorectal Cancer
Exciting findings from the BREAKWATER study: encorafenib and cetuximab combination therapy improves treatment outcomes for patients with BRAF V600E-mutant metastatic colorectal cancer.
Nivolumab: Does the Extended CheckMate-274 Results Prove It’s the Ultimate for MIBC? ASCO GU 2025
The Nivolumab CheckMate-274 trial reveals promising data on overall survival in muscle-invasive bladder cancer.
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care?
The FDA approves Adcetris in a new therapy for adults with relapsed Large B-cell Lymphoma, improving overall survival rates.
FDA Approves Daiichi Sankyo datopotamab / Datroway for Advanced Breast Cancer – Key Trial Data
The FDA has recently approved a game-changing treatment for breast cancer patients. In this video, we break down the approval of datopotamab deruxtecan-dlnk,…
Can Imlunestrant Change the Future of Breast Cancer Treatment? Insights from SABCS with Virginia Kaklamani, MD
Learn about the game-changing EMBER-3 trial. Dive into the results of Imlunestrant, a groundbreaking SERD for ER+, HER2- Advanced Breast Cancer.
FGFR2 Mutations and IDH1 Real-World Data Suggests Caution with Immunotherapy in Specific mBTC
Explore the latest findings from a real-world data analysis on the effectiveness of immunotherapy in treating metastatic biliary tract cancer (mBTC) with spe…
PDAC with ctDNA Study on RMC-6236 Shows Promising Results at ASCO GI – Ignacio Garrido-Laguna, MD
Welcome to OncologyTube.com, where we bring you the latest in oncology research and treatment breakthroughs. In this video, we feature an insightful intervie…